OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.

Creative Commons License

Aydinlar E., Dikmen P., Kosak S., Kocaman A.

The journal of headache and pain, cilt.18, sa.1, ss.23, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1186/s10194-017-0723-4
  • Dergi Adı: The journal of headache and pain
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.23
  • Anahtar Kelimeler: Chronic migraine, Sleep quality, Headache, Analgesic, MIDAS, DASS-21, PREEMPT CLINICAL-PROGRAM, PLACEBO-CONTROLLED PHASE, CHRONIC DAILY HEADACHE, ANXIETY STRESS SCALES, EPISODIC MIGRAINE, OF-LIFE, BOTULINUM-TOXIN, PSYCHOMETRIC PROPERTIES, MEDICATION OVERUSE, DOUBLE-BLIND
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM.